Medican Enterprises (MDCN) 10-K 15 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 14, 2015	Jun. 30, 2014
Document and Entity Information:
Entity Registrant Name	MEDICAN ENTERPRISES, INC.
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Entity Central Index Key	847015
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		447,063,367
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Public Float			$40,433,405

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current asset:
Cash	$79,624
Prepaid deposit	33,000
Total current assets	112,624
Total assets	112,624
Current liabilities:
Accounts payable	1,954,488	176,187
Accrued Interest - related parties		4,172
Convertible Notes Payable (net of discount of $525,500)	5,749,937	0
Promissory Note	176,057
Stock issuance liability	145,578
Notes Payable - related parties		116,529
Total current liabilities	8,026,060	296,888
Derivative liability	389,397
Total liabilities	8,415,457	296,888
Stockholders' Deficit:
Preferred Stock - 5,000,000 shares authorized, $.001 par value; 0 shares issued and outstanding
Common stock - 100,000,000 shares authorized, $.001 par value; 48,769,256 shares issued and outstanding as of December 31, 2014 and 27,151,240 as of December 31, 2013	48,769	27,151
Additional paid-in capital	49,224,550	770,428
Accumulated deficit	-57,576,152	-1,094,467
Total stockholders' deficit	-8,302,833	-296,888
Total liabilities and stockholders' deficit	$112,624

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common Stock, par or stated value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	48,769,256	27,151,240
Common Stock, shares outstanding	48,769,256	27,151,240
Preferred Stock, par or stated value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued
Preferred Stock, shares outstanding
Current Portion
Convertible promissory notes discount	$525,500

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement
REVENUE
OPERATING EXPENSES
Consulting	35,195,854
Legal	1,578,009
Management	14,862,965
Consulting and media relations	43,542
Stock Compensation	4,354,867
Selling, General & Administrative	1,501,640	367,042
Total Operating Expenses	57,536,877	367,042
Loss From Operations	-57,536,877	-367,042
OTHER INCOME (EXPENSE):
Related Party Interest Expense		-9,407
Gain on revaluation of derivative liability	1,559,423	0
Loss on excess of fair value of stock issued over convertible note principal	-107,784
Loss on excess derivative liability over note principal	-436,215	0
NET LOSS	-56,521,453	-376,449
Currency Translation Adjustment	39,767
COMPREHENSIVE LOSS	($56,481,686)	($376,449)
NET LOSS PER BASIC AND DILUTED SHARES	($1.37)	($0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	41,251,844	26,569,076

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)		Common Stock		Additional Paid-In Capital	Accumulated Deficit	Total
Stockholders' Equity, beginning of period, Value at Dec. 31, 2012		$26,501		$588,499	($718,018)	($103,018)
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2012		26,501,240
Common stock issued for services, Value		650	[1]	161,850		162,500
Common stock issued for services, Shares	[1]	650,000
Related party debt forgiveness				9,603		9,603
Contributions from directors				10,476		10,476
Net loss for the year					-376,449	-376,449
Stockholders' Equity, end of period, Value at Dec. 31, 2013		27,151		770,428	-1,094,467	-296,888
Stockholders' Equity, end of period, Shares at Dec. 31, 2013		27,151,240
Private placement - at $0.50 - $1.10, Value		512	[2]	487,798		488,310
Private placement - at $0.50 - $1.10, Shares	[2]	513,110
Subscriptions received, Value		11,155		566,270		567,425
Subscriptions received, Shares		1,154,800
Conversion of related party payables, Value		175		208,281		208,456
Conversion of related party payables, Shares		175,624
Conversion of convertible debt into common stock, Value		174		4,826		5,000
Conversion of convertible debt into common stock, Shares		174,034
Common stock issued for services, Value		19,462	[3]	42,683,225		42,702,687
Common stock issued for services, Shares	[3]	19,460,448
Issuance of warrants				4,155,467		4,155,467
Beneficial conversion price				41,212		41,212
Stock compensation to directors, Value		140		199,260		199,400
Stock compensation to directors, Shares		140,000
Loss on excess of fair value of stock over conversion principal				107,784		107,784
Net loss for the year					-56,481,685	-56,481,686
Stockholders' Equity, end of period, Value at Dec. 31, 2014		$48,769		$49,224,550	($57,576,152)	($8,302,833)
Stockholders' Equity, end of period, Shares at Dec. 31, 2014		48,769,256
[1]	Common stock issued for services at $0.25 per share
[2]	3 Private placements - at $0.50, at $1.00, and at $1.10
[3]	Common stock issued for services pursuant to: Consulting, Legal, and Management

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating Activities:
Comprehensive Loss	($56,481,686)	($376,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Warrants issued as compensation	4,155,467
Stock compensation expenses	199,400
Gain on revaluation of derivative liabilities	-1,559,423	0
Loss on excess of fair value of stock over principal	107,784
Loss on excess of derivative liability over note principal	436,215	0
Convertible note issued on consulting fees	4,450,000
Interest and accretion	1,286,801
Stock Issued for Services:
Consulting	26,591,126	162,500
Management	14,750,000
Legal	1,361,561
Change in operating assets and liabilities:
Prepaid deposit	-33,000
Accounts payable	1,753,566	176,187
Payables to related parties		22,948
Accrued interest - related party		-5,265
Net cash used in operating activities	-2,982,189	-20,079
Financing Activities:
Related party debt forgiveness		9,603
Notes payable	87,755
Convertible notes	1,727,000	0
Demand promissory note	171,323
Subscription agreements	1,075,735
Proceeds from borrowing, related parties		10,476
Net cash provided by financing activities	3,061,813	20,079
Net change in cash in period	79,624
Cash, end of period	79,624
Supplemental Disclosure of Cash Flow Information
Cash paid for interest
Cash paid for taxes
Note payable issued for payables to related party		146,309
Related party debt forgiveness		9,603
Capital stock issued to settle related party debt	43,904
Conversion of convertible note to common stock
Convertible note issued on consulting fees	$4,450,000

Note_1_Organization_and_Summar

Note 1 Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes
Note 1 Organization and Summary of Significant Accounting Policies	NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) Organization
	Medican Enterprises, Inc. (“the Company”) was incorporated in Nevada in October, 1988, under the name Extant Investments, Inc. In 1991, the Company merged with and changed its name to Sentinel Scientific, Inc. From 1991 to 1993, the Company was involved with research and development of biomedical technologies, but ceased active operations due to lack of operating capital. In August, 1993, the Company merged with A.F.C. Entertainment, Inc. (“A.F.C.”), a Barbados corporation, which was involved with the foreign film industry. In December, 1993, the Company purchased all of the shares of Film Optical Investments Limited, a corporation organized in the Province of Ontario, Canada (“Film Opticals”) in exchange for 120,000 of its common shares. With the acquisition of Film Opticals, the Company had been engaged in the business of providing a full range of motion picture printing services and creative titles, credits and optical effects for features, commercials, theatrical and television programs. The foreign film library, acquired with the merger of A.F.C., remained intact, but funding constraints curtailed the Company’s ability to develop and market this business. Because of these constraints, the board of directors elected on December 8, 2004, to sell Film Opticals. The Company is currently considering new business opportunities for its planned principal operations. On August 6, 2013, The Company changed its name to Medican Enterprises, Inc.
	We are a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, the Company is seeking to invest in businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada.  As of the date of this report, the Company has not commenced the actual the production and sale of medical marijuana but is seeking to lay the foundation to commence this business or related business in the marijuana sector.
	We currently have five subsidiaries through which we operate our business.
	Medican Systems Inc. is a corporation incorporated under the laws of the Territory of the Yukon under incorporation number 535642 on December 30, 2013. The authorized share structure is an unlimited number of common shares without par value, with 100 common shares issued to our company, making Medican Systems our direct wholly-owned subsidiary.  The primary focus of Medican Systems is to function as a holding company for Canadian based investments, joint ventures and opportunities.
	Medican (Delta) Systems, Inc. (“Medican Delta”) is a corporation incorporated under the laws of the Province of British Columbia under incorporation number BC0989867 on December 31, 2013 and is a subsidiary of Medican Systems.  The authorized share structure is an unlimited number of common shares without par value, with 100 common shares issued to Medican Systems. The primary focus of Medican Delta is to pursue opportunities in the medical marijuana industry in and around the city of Delta in British Columbia, Canada.
	Canaleaf Systems, Inc. (“CanaLeaf”) is a corporation incorporated under laws of Canada under the Canada Business Corporation Act under incorporation number 883348-6 on March 25, 2014 and is also a subsidiary of Medican Systems.  The authorized share structure is an unlimited number of common shares. CanaLeaf is our operating subsidiary focused on business opportunities in Canada.
	Medican (US) Systems, Inc. (“Medican US”) is a corporation incorporated under laws of Nevada on September 26, 2014 and is also a subsidiary of Medican Systems.  Medican US is our operating subsidiary focused on business opportunities in the United States.
	Medican Nations, LLC (“Medican Nations”) is a corporation incorporated under the laws of Nevada on February 6, 2015 and is also a subsidiary of Medican Systems.  Medican Nations will be focused on building strategic partnerships with Indian communities in the United States and Canada to create and build business solutions within the indoor gardening and marijuana industries.
	The consolidated financial statements of the Company have been prepared in accordance with U. S. generally accepted accounting principles. The consolidated financial statements of the Company include the accounts of Medican Enterprises, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated. The following summarizes the more significant of such policies:
	(b) Statement of Cash Flows
	For purposes of the consolidated statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.
	(c) Income Taxes
	The Company applies the provisions of Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 740 Income Taxes.  The Standard requires an asset and liability approach for financial accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. Due to a loss from inception, the Company has no outstanding tax liability.  At this time the Company has no deferred taxes arising from temporary differences between income for financial reporting and income tax purposes.
	The Company classifies tax-related penalties and net interest on income taxes as income tax expense. As of December 31, 2014 and 2013, no income tax expense had been incurred or accrued.
	(d) Fair Value Measurements and Financial Instruments
	ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:
	Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The carrying value of cash, accounts receivable, investment in a related party, accounts payables, accrued expenses, due to related party, notes payable, and convertible notes approximates their fair values due to their short-term maturities.
	(e) Foreign currency fluctuations and inflationary pressures may have a negative impact on our financial condition and results of operations.
	Our operations in Canada, subject us to foreign currency fluctuations and inflationary pressures which may adversely affect our financial position and results of operations. Since we report our results of operations and financial condition in U.S. dollars, fluctuations in foreign currencies relative to the U.S. dollar may impact our financial results. We do not currently have a hedging program to address foreign currency fluctuations. Any steps taken by us to address foreign currency fluctuations may not eliminate all adverse effects.
	(f) Net Loss Per Common Share
	Basic loss per common share is based on the weighted-average number of shares outstanding. Diluted income or loss per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. There are no common stock equivalents outstanding, thus, basic and diluted income or loss per share calculations are the same.
	(g) Impairment of Long-Lived Assets
	The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value for assets to be used and fair value less disposal costs for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset’s market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued losses associated with assets used to generate revenue. The Company has no long-lived assets as of December 31, 2014 and 2013.
	(h) Use of Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	(i) Revenue Recognition
	The Company shall recognize revenues in accordance with the Securities & Exchange Commission Staff Accounting Bulletin (SAB) number 104, “Revenue Recognition.”  SAB 104 clarifies application of U.S. generally accepted accounting principles to revenue transactions. Accordingly the Company shall recognize revenues when earned which shall be as products or services are delivered to customers. The Company shall also record accounts receivable for revenue earned but not yet collected. An allowance for bad debts shall be provided based on estimated losses. For revenue received in advance of service the Company shall record a current liability as deferred revenue until the earnings process is complete.
	(j) Impact of New Accounting Standards
	The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows.  Based on that review, the Company believes that none of these pronouncements will have a significant effect on its consolidated financial statements.
	(k) Derivative Financial Instruments
	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	(l) Stock Based Compensation
	Shares were issued to various directors as compensation for services rendered. During the year ended December 31, 2014, 140,000 common shares were issued at a value of $199,260.
	During the year ended December 31, 2014, the Company issued 3,230,000 warrants in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the year ended December 31, 2014 amounted to $4,155,467.   The Company also granted 297,832 warrants in connection with convertible note financing and recorded a derivative liability and corresponding debt discount on the convertible note financing in the amount of $195,927. At December 31, 2014, the fair value of this derivative liability relating to the 297,832 warrants had decreased to $nil.

Note_2_Liquiditygoing_Concern

Note 2 Liquidity/going Concern	12 Months Ended
	Dec. 31, 2014
Notes
Note 2 Liquidity/going Concern	NOTE 2 LIQUIDITY/GOING CONCERN
	The Company has an accumulated deficit of $57,576,152 as of December 31, 2014, and has had negative cash flows from operating activities through December 31, 2014 as well as very limited cash resources as of December 31, 2014.  The loss was primarily due to the issuance of common stock and warrants for professional services.  These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Management plans to continue to seek to build the foundations of its medical and recreational marijuana businesses, but it may be unable to do for a number of reasons, including the inability to reach final agreements with its partners and the inability to raise sufficient funds to commence and operate its business.

Note_3_Related_Party_Transacti

Note 3 Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2014
Notes
Note 3 Related Party Transactions and Balances	NOTE 3 RELATED PARTY TRANSACTIONS AND BALANCES
	On December 31, 2014, total balances due to related parties amounted to $0 (2013 - $116,529).  Various loans have been obtained through related parties in the prior year. These loans constituted the balance of the related party payables as of December 31, 2013. During the year ended December 31, 2014, the Company settled amounts payable to related parties by issuance of 175,624 shares of common stock valued at $208,456 which is valued at the market value of shares at the date of issuance.

Note_4_Equity

Note 4 Equity	12 Months Ended
	Dec. 31, 2014
Notes
Note 4 Equity	NOTE 4 EQUITY
	On August 16, 2013, the Company’s board of directors approved a forward split paid as a stock dividend, on a basis of 20:1 (the “Stock Dividend”), pursuant to which, the Company’s shareholders as at September 24, 2013 received twenty (20) shares of our Company’s common stock for each one (1) share of common stock currently held. The pay-out date as approved by the board of directors and Financial Industry Regulatory Authority is September 25, 2013.
	On October 4, 2013, 20,000 shares were issued to individuals in exchange for services. The shares were valued at $0.25 per share and had a par value of $0.001.
	On November 25, 2013, 600,000 shares were issued to individuals in exchange for services. The shares were valued at $0.25 per share and had a par value of $0.001.
	On December 6, 2013, 30,000 shares were issued in exchange for services. The shares were valued at $0.25 per share and had a par value of $0.001.
	On April 23, 2014, the Company filed an Amendment to its Articles of Incorporation with the Nevada Secretary of State increasing its authorized shares to 100,000,000 shares, par value $0.001 per share.
	During the year ended December 31, 2014, the Company:
	i.      Issued 1,726,910 common shares for proceeds of $1,075,735 pursuant to private placements.
	ii.     Issued 140,000 common shares valued at $197,400 to officers and employees and recorded stock compensation expense at the market value of shares at the date of issuance.
	iii.    Issued 175,624 common shares to a shareholder pursuant to settlement of notes payable of $208,281 due to a shareholder.
	iv.    Issued to various consultants 13,861,814 common shares valued at $26,591,126, as payment for consulting services.  Shares were valued as of their respective issuance dates throughout the period.
	v.     Issued 598,634 common shares valued at $1,361,561 as payment for legal services. Shares were valued as of their respective issuance dates throughout the period.
	vi.    Issued 5,000,000 common shares valued at $14,750,000 as payment for management services. Shares were valued as of their respective issuance dates throughout the period.
	During the year ended December 31, 2014, the Company issued 3,230,000 warrants issued in connection with the share issuances and subscriptions that occurred during the year. The fair value of these warrants was determined to be $6,643,981, which is calculated using the Black-Scholes method and the following assumptions: volatility 120-128%, risk-free rate 0.2%-0.3%, 0% dividends. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the year ending December 31, 2014 amounted to $4,155,467.
	During the year ended December 31, 2014, the Company issued 1,599,910 warrants in connection with private placements that occurred during the year.  The warrants are exercisable into one common share at $0.50 to $1.50 per warrant, expiring June 30, 2015.  The Company also issued 297,832 warrants in connection with a $1,500,000 convertible note (Note 7 (d)).
	A summary of the warrants issued as of December 31, 2014 and 2013 is as follows:
		Number	Weighted Average Exercise Price
	Outstanding at December 31, 2013	-	$-
	Issued	5,127,742	0.7
	Exercised	-	-
	Outstanding and exercisable at December 31, 2014	5,127,742	$0.70

Note_6_Cash

Note 6 Cash	12 Months Ended
	Dec. 31, 2014
Notes
Note 6 Cash	NOTE 6 CASH
	As of December 31, 2014, total cash balances amounted to $79,624. Of this amount, $46,554 is held in a bank account denominated in Canadian dollars. Because the reporting company reports all balances in US Dollars, transactions over the course of the period which were denominated in Canadian dollars were adjusted as of December 31, 2014 to reflect their value in US Dollars. The effect of this is a foreign currency translation adjustment of $39,767 on the Statement of Operations.

Note_7_Notes_Payable

Note 7 Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes
Note 7 Notes Payable	NOTE 7 NOTES PAYABLE
	(a)           $115,000 March 31, 2014 LG Capital/Adar Bays Convertible Notes
	On March 31, 2014, the Company issued two convertible notes in the principal amounts of $57,500 each. The notes mature on March 31, 2015, are 8% per annum convertible notes and each includes a 5% original issue discount such that the total proceeds to the Company from issuance of the two notes is $115,000 and the purchase price for each note is $55,000.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days.  Interest shall be paid by the Company in common stock.
	The Company recorded a derivative liability of $84,506 from the variable conversion pricing of the convertible note and recorded accretion expense of $84,506 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $56,295 during the year ended December 31, 2014, resulting in an ending derivative liability balance of $28,211.
	During the three months ended December 31, 2014, the debtors elected to convert $65,321  in convertible debt principal and interest into 1,189,299 shares of common stock with an aggregate fair value of $91,960, representing the fair value of the derivative liabilities and the amortized cost of convertible debt settled was included as additional paid-in capital.  During the year ended December 31, 2014, the Company recorded a loss of $26,639 on the excess of fair value of stock issued over the converted principal amount.  As at December 31, 2014, the stock has not been issued, and the conversion value of $65,321 has been recorded to stock issuance liability.  At December 31, 2014, the convertible note principal and interest balances are $54,875.
	The back-end notes entered into on March 31, 2014, with face values of $57,500 each was funded and the Company received the funds on October 22, 2014 and December 11, 2014. The Company issued two convertible notes in the principal amounts of $57,500 each. The note matures on March 31, 2015, are 8% per annum convertible notes and each includes a 5% original issue discount such that the total proceeds to the Company from issuance of the note is $55,000 and the purchase price for each note is $55,000.  The back-end notes were also amended such that the conversion price for each share is 65% of the lowest closing bid price for twenty prior trading days.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  Interest shall be paid by the Company in common stock. At December 31, 2014, the back-end convertible note principal and interest balances are $115,835.
	The Company recorded a derivative liability of $80,028 from the variable conversion pricing of the convertible note and recorded accretion expense of $14,543 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $48,145 during the year ended December 31, 2014, resulting in an ending derivative liability balance of $31,883.
	Subsequent to December 31, 2014, the debtor elected to convert $15,000 of convertible debt principal into 1,775,148 shares of common stock with an aggregate fair value of $71,006 which is the market trading price at date of conversion.
	(b)           $100,000 May 8, 2014 JSJ Investments Convertible Note
	On May 8, 2014, the Company issued a 12% convertible note in exchange for cash received of $100,000.  The Company must pay 12% interest per annum on the unpaid principal balance, and the principal balance was due on November 8, 2014.  Upon maturity date, the note has a cash redemption premium of 130% of the principal amount.  The note may be converted to stock at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion.
	The Company recorded a derivative liability of $129,359 from the variable conversion pricing of the convertible note and recorded accretion expense of $129,359 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014. As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the statement of operations of $28,333 for the year ending December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $128,978, during the year ended December 31, 2014, resulting in an ending derivative liability balance of $381.
	During the three months ended December 31, 2014, the debtor elected to convert $50,000 in convertible debt principal into 568,064 shares of common stock with an aggregate fair value of $96,571, representing the fair value of the derivative liabilities and the amortized cost of convertible debt settled was included as additional paid-in capital. During the year ended December 31, 2014, the Company recorded a loss of $46,571 on the excess of fair value of stock issued over the converted principal amount.  As at December 31, 2014, the stock has not been issued, and the conversion value of $50,000 has been recorded to stock issuance liability.  At December 31, 2014, the convertible note principal and interest balance is $57,118.
	(c)           $1,105,000 June 4, 2014 Typenex Convertible Note
	On June 4, 2014, the Company issued a 10% secured convertible promissory note in the principal amount of $1,105,000. The Company must pay 10% interest per annum on the unpaid principal balance which is due November 4, 2015.  The purchase price for the note is $1,000,000, computed as $1,105,000 original principal balance, less the original issue discount (“OID”) of $100,000, less the transaction cost of $5,000.  On the closing date, the investor shall pay the purchase price to the Company by delivering the following at closing:
	a)                    The initial cash purchase price of $170,000 and $15,000 of the OID (received)
	b)                    Secured investor note #1 in the principal amount of $85,000 and $8,500 of the OID
	c)                     Secured investor note #2 in the principal amount of $85,000 and $8,500 of the OID)
	d)                    Secured investor note #3 in the principal amount of $85,000 and $8,500 of the OID
	e)                     Secured investor note #4 in the principal amount of $85,000 and $8,500 of the OID
	f)                     Investor note #5 in the principal amount of $85,000 and $8,500 of the OID
	g)                     Investor note #6 in the principal amount of $85,000 and $8,500 of the OID
	h)                    Investor note #7 in the principal amount of $85,000 and $8,500 of the OID
	i)                      Investor note #8 in the principal amount of $85,000 and $8,500 of the OID
	j)                     Investor note #9 in the principal amount of $85,000 and $8,500 of the OID)                       Investor note #10 in the principal amount of $85,000 and $8,500 of the OID
	The conversion price for each lender conversion shall be $1.65.  Lender has the right at any time after the purchase price date to convert all or any part of the outstanding balance into shares of common stock. During the year ended December 31, 2014, the Company received the first tranche of $170,000 less transaction cost.
	As the conversion price at the date of issuance of the note was less than the Company’s market trading price of $2.04 on June 4, 2014, the Company recorded a beneficial conversion feature of $41,212 against additional paid-in capital and recorded accretion expense of $16,453 for the year ended December 31, 2014.
	During the three months ended December 31, 2014, the debtor elected to convert $30,000 in convertible debt principal into 807,168 shares of common stock with an aggregate fair value of $64,573, representing the fair value of the derivative liabilities and the amortized cost of convertible debt settled was included as additional paid-in capital.  During the year ended December 31, 2014, the Company recorded a loss of $34,573 on the excess of fair value of stock issued over the converted principal amount.  As at December 31, 2014, the stock has not been issued, and the conversion value of $30,000 has been recorded to stock issuance liability. At December 31, 2014, the convertible note principal and interest balance is $159,675.
	(d)           $1,500,000 June 25, 2014 Himmil Convertible Note
	On June 25, 2014, the Company entered into a Securities Purchase Agreement (the “Agreement”) with a single accredited investor (the “Investor”) in a private placement pursuant to which the Investor purchased a 5% Convertible Note with a face amount of $1,500,000 for a purchase price of $1,000,000  (the “Note”).  The Note bears interest at a rate of 5% per annum and is payable one year after the date of the issuance.  The Company may pay interest due either in cash or, at its option, through freely tradable stock.  The Note will be convertible at the option of the Investor at any time into shares of the Company’s common stock at a conversion price equal to the less of (i) $1.90 and (ii) 70% (60% in the event of default) of the average of the two lowest volume-weighted-average-price of the Common Stock during the 12 consecutive trading days immediately preceding the applicable conversion date.  All or part of the then remaining principal amount of the Note may be prepaid at any time at a price equal to 125% of the sum of the remaining principal amount of the Note to be prepaid plus all accrued and unpaid interest thereon.  The principal amount of the Note will be reduced by $500,000 if the shares of Common Stock underlying the Note are registered for public resale pursuant to an effective registration statement by August 24, 2014.  As at December 31, 2014, the carrying amount of this Convertible Note is $808,043, net of a $500,000 original issuer discount.
	At September 1, 2014, due to the issuance of a separate convertible note which violates the Agreement, the interest rate on the Convertible Note increased from 5% to 18%.
	In connection with the Agreement, the Investor received a warrant to purchase 297,832 shares of common stock, exercisable for a period of 5 years from the date of issuance at exercise price of $2.15, subject to adjustment.  If a registration statement is not effective for the resale by the Holder of all of the Warrant Shares, the Investor may exercise the warrant on a “cashless” basis. The conversion price of the Note and the exercise price of the Warrant are subject to “full ratchet” anti-dilution adjustment for subsequent lower price issuances by the Company, as well as customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like.  During the year ended December 31, 2014, the Company recorded $195,927 as a derivative liability on the issuance of these warrants.  At December 31, 2014, the derivative liability from the issuance of warrants was revalued, resulting in a gain on revaluation of derivative liability of $195,927.  During the year ended December 31, 2014, the Company recorded accretion expense of $101,453 on the derivative liability of these warrants.  At December 31, 2014, the convertible note principal and interest balance is $1,603,476.
	The Company recorded a derivative liability of $1,164,745 from the variable conversion pricing of the convertible note and recorded accretion expense of $603,114 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the profit and loss of $360,672 for the year ending December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $1,099,709, resulting in an ending derivative liability balance at December 31, 2014 of $261,209.
	Subsequent to December 31, 2014, the debtor elected to convert $221,122 in convertible debt principal into 27,822,391 shares of common stock with an aggregate fair value of $503,352 which is the market trading price at respective dates of conversion.
	(e)           $83,500 September 1, 2014 KBM Worldwide Convertible Note
	On September 1, 2014, the Company issued a convertible note in the principal amount of $83,500. The note matures on June 1, 2015 and bears 8% interest per annum.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 58% of the average of the 3 lowest closing bid prices for ten prior trading days.
	The Company recorded a derivative liability of $85,871 from the variable conversion pricing of the convertible note and recorded accretion expense of $39,211 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the profit and loss of $4,967 for the year ended December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $76,440 during the year ended December 31, 2014, resulting in an ending derivative liability balance of $9,431. At December 31, 2014, the convertible note principal and interest balance is $87,362.
	(f)            $82,688 September 12, 2014 LG Capital Convertible Note
	On September 12, 2014, the Company issued a convertible note in the principal amount of $82,688. The note matures on September 12, 2015 and bears 8% interest per annum.  The note contains a 5% original issue discount such that the purchase price is $78,750. At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be payable in common stock.
	The Company recorded a derivative liability of $68,933 from the variable conversion pricing of the convertible note and recorded accretion expense of $21,175 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $59,964 during the year ended December 31, 2014, resulting in an ending derivative liability balance of $8,969. At December 31, 2014, the convertible note principal and interest balance is $86,185.
	(g)           $4,450,000 October 1, 2014 Green Grow LLC Convertible Note
	On October 1, 2014, the Company issued convertible notes to various debtors in the principal amount of $4,450,000 in received consideration of consulting expenses from the debtors.  The note matures on April 1, 2015 and bears 10% interest per annum.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 50% of the average of the lowest closing bid price for twenty prior trading days. Interest shall be payable in common stock. At December 31, 2014, the convertible note principal and interest balance is $4,560,945.
	(h)           $75,000 November 25, 2014 Tangiers Convertible Note
	On November 25, 2014, the Company issued a convertible note in the principal amount of $220,000.  The initial amount received by the Company was $75,000, with an additional $7,500 of the financing retained by the debtor through an original issuer discount.  The debtor has the option to finance additional amounts up to the balance of $220,000 until May 25, 2015.  The note matures on November 25, 2015 and bears 10% interest per annum.  The note contains a 5% original issue discount such that the purchase price is $78,750. At the option of the holder, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 58% of the lowest closing bid prices for ten prior trading days.
	The Company recorded a derivative liability of $78,148 from the variable conversion pricing of the convertible note and recorded accretion expense of $4,926 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014. As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the statement of operations of $14,596 for the year ending December 31, 2014.  At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $52,651 during the year ended December 31, 2014, resulting in an ending derivative liability balance of $25,497. At December 31, 2014, the convertible note principal and interest balance is $84,966.
	(i)            $43,000 November 26, 2014 KBM Worldwide Convertible Note
	On November 26, 2014, the Company issued a convertible note in the principal amount of $43,000 .  The note matures on August 28, 2015 and bears 8% interest per annum.  At the option of the holder, beginning May 13, 2015, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 42% of the lowest three closing bid prices for ten prior trading days.
	The Company recorded a derivative liability of $61,303 from the variable conversion pricing of the convertible note and recorded accretion expense of $2,173 relating to the derivative liability from variable conversion pricing during the year ended December 31, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the statement of operations of $26,621 for the year ending December 31, 2014. At December 31, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $37,487 during the year ended December 31, 2014, resulting in an ending derivative liability balance of $23,816. At December 31, 2014, the convertible note principal and interest balance is $44,178.
	The carrying value of convertible debentures are as follows:
		2014	2013
	Balance of convertible debentures, beginning of year	$-	$-
	Proceeds from new convertible debt tranches	1,727,000	-
	Convertible debt issued on consulting fees	4,450,000
	Derivative liability of variable conversion price	-1,794,105	-
	Derivative liability of warrants	-195,927	-
	Excess of derivative liability of conversion price on principal amount	436,215	-
	Interest accrued on principal	239,434	-
	Accretion of derivative liability of conversion price	1,032,636	-
	Conversion Of Convertible Debt	(145,315)	-
	Balance of convertible debentures, end of year	$5,749,937	$-
	The fair value of derivative liabilities are as follows:
		2014	2013
	Fair value of derivative liabilities, beginning of year	$-	$-
	Fair value of derivative liability at inception of new tranches	1,752,893	-
	Fair value of derivative liability of warrants	195,928	-
Gain of revaluation of derivative liability	(1,559,423)	-
Fair value of derivative liabilities, end of year	$389,397	$-
(j)            $200,000 CDN October 1, 2014 Demand Promissory Note
On October 1, 2014, the Company received CDN $200,000 (US $171,323) pursuant to a demand promissory note agreement.  The note bears interest at 12% per annum, calculated yearly and is due and payable in full on demand.  Interest is due and payable annually on the first day of January of each year and must be paid no later than September 30, 2015.

Note_8_Subscription_Agreement

Note 8 Subscription Agreement	12 Months Ended
	Dec. 31, 2014
Notes
Note 8 Subscription Agreement	NOTE 8 SUBSCRIPTION AGREEMENT
	Under the Amendment to the Subscription Agreement that was entered into on April 29, 2014, the Company agreed to acquire a 51% interest in International Herbs Medical Marijuana Ltd. (“IHMML”), a company that is applying to obtain licensed producer status from Health Canada.
	On July 25, 2014, the Company and CanaLeaf entered into a non-binding letter of intent with Zenabis Limited Partnership (“Zenabis”) and IHMML. In September 2014, the Company announced that due to structuring and regulatory issues, the prospects for consummating this restructuring are uncertain and that although the Company will continue to monitor this situation, the Company was turning to focus on other potential opportunities.  As such, no assurances can be given that the transactions described in such non-binding letter of intent will be effectuated, and the Company is focusing on other operational activities at this time.

Note_9_Property

Note 9 Property	12 Months Ended
	Dec. 31, 2014
Notes
Note 9 Property	NOTE 9 PROPERTY
	On December 2, 2014, the Company signed an agreement to acquire a 67,000 square foot facility in Phoenix, Arizona which the company plans to lease as a marijuana growing and warehouse facility to licensed growers.  The industrial building sits on 2.55 acres of industrial zoned land. The anticipated final purchase price for the property is $2,340,310 and a closing is planned during the first half of 2015 pending, among other closing conditions, a variance to zone the building for the cultivation of marijuana. The acquisition of this property will launch Medican’s real estate and leasing services business under which the company would lease real estate that is outfitted with turnkey solutions for legally compliant growing facilities to licensed growers.

Note_10_Income_Taxes

Note 10 Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes
Note 10 Income Taxes	NOTE 10 INCOME TAXES
	The provision for income taxes consists of the following:
		2014	2013
	Current tax	$-	$-
	Deferred tax benefit	-19,217,294	-127,993
	Benefits of operating loss carryforwards	19,217,294	127,993
	Provision for Income Tax	$-	$-
	Below is a summary of deferred tax asset calculations on net operating loss carry forward amounts as of December 31, 2014:
		NOL Balance	Tax	Rate
	Net operating loss	$10,266,101	$3,490,474	34%
	Related party interest accrual	9,407	3,198	34%
	Warrants issued as compensation	4,155,467	1,412,859	34%
	Stock compensation expense	199,400	67,796	34%
	Stock issued for services	42,702,687	14,518,914	34%
	Other items	271,377	92,268	34%
	Valuation allowance		-19,585,509
	Deferred tax asset, December 31, 2014		$-
	Below is a summary of deferred tax asset calculations on net operating loss carry forward amounts as of December 31, 2013:
		NOL Balance	Tax	Rate
	Net operating loss	$1,073,579	$365,017	34%
	Related party interest accrual	9,407	3,198	34%
	Valuation allowance		-368,215
	Deferred tax asset, December 31, 2013		$-
	A valuation allowance is provided when it is more likely than not that some portion of the deferred tax asset will not be realized.  Currently there is no reasonable assurance that the Company will be able to take advantage of a deferred tax asset. Thus, an offsetting allowance has been established for the deferred asset.  The valuation allowance has increased by $16,998,435, from the prior year balance of $368,215, as of December 31, 2013.
	The Company has the following operating loss carry forwards available at December 31, 2014:
	Operating Losses Expires	Amount
	2020	$38,250
	2021	12,382
	2022	17,151
	2023	14,274
	2024	529,784
	2025	32,564
	2026	6,488
	2027	7,905
	2028	14,696
	2029	6,905
	2030	8,636
	2031	8,035
	2032	9,467
	2033	367,042
	2034	9,192,522
	Total	$10,266,101
	Reconciliation between income taxes at the statutory tax rate (34%) and the actual income tax provision for continuing operations follows:
		2014	2013
	Expected Tax Provision	$19,217,294	($127,993)
	Effect of:
	Increase in Valuation Allowance	-19,217,294	127,993
	Actual Tax Provision	$-	$-
	Uncertain Tax Positions
	The Company has not made any adjustments to deferred tax asset or liabilities.  The Company did not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed.  The Company has not had operations and is carrying a Net Operating Loss as disclosed above.  Since it is not unlikely that the Net Operating loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.
	The Company has filed income tax returns in the U.S.  All years prior to 2011 are closed by expiration of the statute of limitations.  The tax year ended December 31, 2011, will close by expiration of the statute of limitations on April 15, 2015.  The years ended December 31, 2012, 2013 and 2014 are open for examination.

Note_11_Subsequent_Events

Note 11 Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes
Note 11 Subsequent Events	NOTE 11 SUBSEQUENT EVENTS
	On January 14, 2015, the Company issued a convertible note in the principal amount of $54,000 to KBM Worldwide.  The note matures on October 16, 2015 and bears 8% interest per annum.  At the option of the holder, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 58% of the lowest three closing bid prices for ten prior trading days.
	On January 16, 2015, the Company issued a convertible note in the principal amount of $100,000 to RDW Capital.  The holder will pay $45,000 upon execution (received) and $45,000 once the 14C is effective. The note matures on July 16, 2015 and bears 10% interest per annum.  At the option of the holder, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 35% of the lowest twenty closing bid prices for ten prior trading days.
	On January 20, 2015, the Company entered into a purchase agreement to acquire a 7,200 square foot retail and commercial property in Phoenix, Arizona. The property is currently leased through August 2018 to an Arizona state licensed medical marijuana dispensary. Per the purchase agreement, the lease agreement will be assigned to Medican. The rental amount of the current lease is in excess of $200,000 annually, triple net. The lease provides for two five-year tenant renewal options. The lease rate increases at 3 percent per year or CPI, whichever is greater. Total purchase price for the property is $2,250,000, which Medican expects to pay through a combination of mortgage debt and an $850,000 convertible promissory note secured by the property. The property’s value has been appraised at $2,385,000 and was substantiated by an independent appraiser, Kalinowski & Associates.  As per the Amendment No. 2 and 3 to the original agreement, the closing for the purchase of this property is expected to occur on or before May 31, 2015.
	On January 30, 2015, the Company issued a convertible note in the principal amount of $66,000 to Black Mountain Equities, Inc.  The note bears an original issue discount of $6,000.  The note matures on January 30, 2016 and bears 10% interest per annum.  At the option of the holder, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is the lesser of $0.03 or 60% of the lowest three closing bid prices for twenty prior trading days.
	On February 16, 2015, the Company filed with the State of Nevada a Certificate of Amendment to its Articles of Incorporation increasing the authorized amount of shares of common stock to 1,000,000,000 shares, par value $0.001 per shares. The Company is also authorized, according to the Definitive Information Statement dated January 26, 2015, to enact a reverse split in an amount up to 1:10 according to the Board of Director’s discretion.
	On February 19, 2015, the Company entered into a 10% convertible debenture with RDW Capital, LLC (“RDW”) in the principal amount of $25,000 (the "RDW Note"). The financing on the initial amount closed on March 23, 2015.
	The principal due under the RDW Note bears interest at the rate of 10% per annum. Upon an event of default, the outstanding balance shall immediately be due in cash and shall incur a late fee of $1,000 per day The principal and interest underlying the RDW Note is convertible at any time into common stock, at RDW’s option, and will be equal to 35% of the lowest trading price of the Company’s common stock during the twenty consecutive trading days prior to the date on which RDW (or the then-holder of the RDW) elects to convert all or part of the RDW Note. In connection therewith, the Company agreed to reserve from its authorized and unissued shares at least the number of shares that may be issuable upon conversion of the note once the Company has increased its authorized shares. The Company may prepay any portion of the principal amount at 130% of such amount along with any accrued interest of the RDW Note at any time upon seven days’ written notice to RDW.
	On March 12, 2015, the Company entered into an 8% convertible promissory note with Vis Vires, Inc. (“Vis Vires”) in the principal amount of $43,000 (the "Vis Vires Note"). The financing on the initial amount closed on March 18, 2015.
	The principal due under the Vis Vires Note bears interest at the rate of 8% per annum. Upon an event of default, the outstanding balance shall immediately increase to 150% of the outstanding balance immediately prior to the event of default.  The principal and interest underlying the Vis Vires Note is convertible at any time into common stock, at Vis Vires’s option, and will be equal to 58% of the average of the lowest three trading price of the Company’s common stock during the ten consecutive trading days prior to the date on which Vis Vires (or the then-holder of the Vis Vires) elects to convert all or part of the Vis Vires Note. In connection therewith, the Company agreed to reserve from its authorized and unissued shares at least the number of shares that may be issuable upon conversion of the note once the Company has increased its authorized shares. The Company may prepay any portion of the principal amount at between 115% and 145% of such amount along with any accrued interest of the Vis Vires Note at any time upon seven days’ written notice to Vis Vires.

Note_1_Organization_and_Summar1

Note 1 Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
(b) Statement of Cash Flows	(b) Statement of Cash Flows
	For purposes of the consolidated statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.
(c) Income Taxes	(c) Income Taxes
	The Company applies the provisions of Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 740 Income Taxes.  The Standard requires an asset and liability approach for financial accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. Due to a loss from inception, the Company has no outstanding tax liability.  At this time the Company has no deferred taxes arising from temporary differences between income for financial reporting and income tax purposes.
	The Company classifies tax-related penalties and net interest on income taxes as income tax expense. As of December 31, 2014 and 2013, no income tax expense had been incurred or accrued.
(d) Fair Value Measurements and Financial Instruments	(d) Fair Value Measurements and Financial Instruments
	ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:
	Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The carrying value of cash, accounts receivable, investment in a related party, accounts payables, accrued expenses, due to related party, notes payable, and convertible notes approximates their fair values due to their short-term maturities.
(e) Foreign Currency	(e) Foreign currency fluctuations and inflationary pressures may have a negative impact on our financial condition and results of operations.
	Our operations in Canada, subject us to foreign currency fluctuations and inflationary pressures which may adversely affect our financial position and results of operations. Since we report our results of operations and financial condition in U.S. dollars, fluctuations in foreign currencies relative to the U.S. dollar may impact our financial results. We do not currently have a hedging program to address foreign currency fluctuations. Any steps taken by us to address foreign currency fluctuations may not eliminate all adverse effects.
(f) Net Loss Per Common Share	(f) Net Loss Per Common Share
	Basic loss per common share is based on the weighted-average number of shares outstanding. Diluted income or loss per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. There are no common stock equivalents outstanding, thus, basic and diluted income or loss per share calculations are the same.
(g) Impairment of Long-lived Assets	(g) Impairment of Long-Lived Assets
	The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value for assets to be used and fair value less disposal costs for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset’s market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued losses associated with assets used to generate revenue. The Company has no long-lived assets as of December 31, 2014 and 2013.
(h) Use of Estimates in Preparation of Financial Statements	(h) Use of Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
(i) Revenue Recognition	(i) Revenue Recognition
	The Company shall recognize revenues in accordance with the Securities & Exchange Commission Staff Accounting Bulletin (SAB) number 104, “Revenue Recognition.”  SAB 104 clarifies application of U.S. generally accepted accounting principles to revenue transactions. Accordingly the Company shall recognize revenues when earned which shall be as products or services are delivered to customers. The Company shall also record accounts receivable for revenue earned but not yet collected. An allowance for bad debts shall be provided based on estimated losses. For revenue received in advance of service the Company shall record a current liability as deferred revenue until the earnings process is complete.
(j) Impact of New Accounting Standards	(j) Impact of New Accounting Standards
	The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows.  Based on that review, the Company believes that none of these pronouncements will have a significant effect on its consolidated financial statements.
(k) Derivative Financial Instruments	(k) Derivative Financial Instruments
	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
(l) Stock Based Compensation	(l) Stock Based Compensation
	Shares were issued to various directors as compensation for services rendered. During the year ended December 31, 2014, 140,000 common shares were issued at a value of $199,260.
	During the year ended December 31, 2014, the Company issued 3,230,000 warrants in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the year ended December 31, 2014 amounted to $4,155,467.   The Company also granted 297,832 warrants in connection with convertible note financing and recorded a derivative liability and corresponding debt discount on the convertible note financing in the amount of $195,927. At December 31, 2014, the fair value of this derivative liability relating to the 297,832 warrants had decreased to $nil.

Note_4_Equity_Summary_of_Warra

Note 4 Equity: Summary of Warrants Issued (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Summary of Warrants Issued	A summary of the warrants issued as of December 31, 2014 and 2013 is as follows:
		Number	Weighted Average Exercise Price
	Outstanding at December 31, 2013	-	$-
	Issued	5,127,742	0.7
	Exercised	-	-
	Outstanding and exercisable at December 31, 2014	5,127,742	$0.70

Note_7_Notes_Payable_Schedule_

Note 7 Notes Payable: Schedule of Fair Value Convertible Debentures (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Fair Value Convertible Debentures	The carrying value of convertible debentures are as follows:
		2014	2013
	Balance of convertible debentures, beginning of year	$-	$-
	Proceeds from new convertible debt tranches	1,727,000	-
	Convertible debt issued on consulting fees	4,450,000
	Derivative liability of variable conversion price	-1,794,105	-
	Derivative liability of warrants	-195,927	-
	Excess of derivative liability of conversion price on principal amount	436,215	-
	Interest accrued on principal	239,434	-
	Accretion of derivative liability of conversion price	1,032,636	-
	Conversion Of Convertible Debt	(145,315)	-
	Balance of convertible debentures, end of year	$5,749,937	$-

Note_7_Notes_Payable_Schedule_1

Note 7 Notes Payable: Schedule of Fair Value of Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Fair Value of Derivative Liabilities	The fair value of derivative liabilities are as follows:
		2014	2013
	Fair value of derivative liabilities, beginning of year	$-	$-
	Fair value of derivative liability at inception of new tranches	1,752,893	-
	Fair value of derivative liability of warrants	195,928	-
	Gain of revaluation of derivative liability	(1,559,423)	-
	Fair value of derivative liabilities, end of year	$389,397	$-

Note_10_Income_Taxes_Schedule_

Note 10 Income Taxes: Schedule of Components of Income Tax (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Components of Income Tax	The provision for income taxes consists of the following:
		2014	2013
	Current tax	$-	$-
	Deferred tax benefit	-19,217,294	-127,993
	Benefits of operating loss carryforwards	19,217,294	127,993
	Provision for Income Tax	$-	$-

Note_10_Income_Taxes_Schedule_1

Note 10 Income Taxes: Schedule of Deferred Tax Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Deferred Tax Assets	Below is a summary of deferred tax asset calculations on net operating loss carry forward amounts as of December 31, 2014:
		NOL Balance	Tax	Rate
	Net operating loss	$10,266,101	$3,490,474	34%
	Related party interest accrual	9,407	3,198	34%
	Warrants issued as compensation	4,155,467	1,412,859	34%
	Stock compensation expense	199,400	67,796	34%
	Stock issued for services	42,702,687	14,518,914	34%
	Other items	271,377	92,268	34%
	Valuation allowance		-19,585,509
	Deferred tax asset, December 31, 2014		$-
	Below is a summary of deferred tax asset calculations on net operating loss carry forward amounts as of December 31, 2013:
		NOL Balance	Tax	Rate
	Net operating loss	$1,073,579	$365,017	34%
	Related party interest accrual	9,407	3,198	34%
	Valuation allowance		-368,215
	Deferred tax asset, December 31, 2013		$-

Note_10_Income_Taxes_Summary_o

Note 10 Income Taxes: Summary of Operating Loss Carryforwards Expirations (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Summary of Operating Loss Carryforwards Expirations	The Company has the following operating loss carry forwards available at December 31, 2014:
	Operating Losses Expires	Amount
	2020	$38,250
	2021	12,382
	2022	17,151
	2023	14,274
	2024	529,784
	2025	32,564
	2026	6,488
	2027	7,905
	2028	14,696
	2029	6,905
	2030	8,636
	2031	8,035
	2032	9,467
	2033	367,042
	2034	9,192,522
	Total	$10,266,101

Note_10_Income_Taxes_Schedule_2

Note 10 Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	Reconciliation between income taxes at the statutory tax rate (34%) and the actual income tax provision for continuing operations follows:
		2014	2013
	Expected Tax Provision	$19,217,294	($127,993)
	Effect of:
	Increase in Valuation Allowance	-19,217,294	127,993
	Actual Tax Provision	$-	$-

Note_1_Organization_and_Summar2

Note 1 Organization and Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended	12 Months Ended
	Dec. 31, 1993	Dec. 31, 2014	Dec. 31, 2013
Common Stock Shares Issued in Exchange for Purchases of shares of Film Opticals	120,000
Common Stock, par or stated value		0.001	$0.00
Medican Systems
Entity Incorporation, Date of Incorporation		30-Dec-13
Medican Systems | Common Stock
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions		100
Medican (Delta)
Entity Incorporation, Date of Incorporation		31-Dec-13
Common Stock, par or stated value		0
Medican (Delta) | Common Stock
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions		100
Canaleaf Systems
Entity Incorporation, Date of Incorporation		25-Mar-14
Medican (US) Systems, Inc.
Entity Incorporation, Date of Incorporation		26-Sep-14
Film Optical Investments Limited
Entity Information, Date to Change Former Legal or Registered Name		6-Aug-13

Note_1_Organization_and_Summar3

Note 1 Organization and Summary of Significant Accounting Policies: (c) Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Provision for Income Tax	$0	$0

Note_1_Organization_and_Summar4

Note 1 Organization and Summary of Significant Accounting Policies: (f) Net Loss Per Common Share (Details)	12 Months Ended
	Dec. 31, 2014
Details
Weighted Average Number Diluted Shares Outstanding Adjustment	0

Note_1_Organization_and_Summar5

Note 1 Organization and Summary of Significant Accounting Policies: (l) Stock Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Common stock issued for services, Value	$42,702,687		$162,500
Common Stock
Common stock issued for services, Shares	19,460,448	[1]	650,000	[2]
Common stock issued for services, Value	19,462	[1]	650	[2]
Common Stock | Various Employees
Common stock issued for services, Shares	140,000
Common stock issued for services, Value	199,260
Warrant
Allocated Share-based Compensation Expense	4,155,467
Warrant | $1,500,000 June 25, 2014 Convertible Note
Warrants, Issued	297,832
Derivative Liability	195,927
Derivative Liability, Fair Value	0
Warrant | Subscriptions
Warrants, Issued	3,230,000
Fair Value of Warrants	$6,643,981
[1]	Common stock issued for services pursuant to: Consulting, Legal, and Management
[2]	Common stock issued for services at $0.25 per share

Note_2_Liquiditygoing_Concern_

Note 2 Liquidity/going Concern (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Accumulated deficit	($57,576,152)	($1,094,467)

Note_3_Related_Party_Transacti1

Note 3 Related Party Transactions and Balances (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Due to Related Parties	$0	$116,529
Debt Conversion, Original Debt, Amount	145,315	0
Investor | Common Stock
Shares Issued Pursuant to Debt Conversion	175,624
Debt Conversion, Original Debt, Amount	$208,456

Note_4_Equity_Details

Note 4 Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Jun. 25, 2014
Common Stock, par or stated value	$0.00		$0.00
Common Stock, shares authorized	100,000,000		100,000,000
Private placement - at $0.50 - $1.10, Value	$488,310
Common stock issued for services, Value	42,702,687		162,500
Conversion of related party payables, Value	208,456
Himmil Convertible Note
Debt Instrument, Face Amount	1,500,000				1,500,000
Private Placement | Minimum
Exercise Price of Warrants	$0.50
Private Placement | Maximum
Exercise Price of Warrants	$1.50
Common Stock
Stockholders' Equity Note, Stock Split			On August 16, 2013, the Company’s board of directors approved a forward split paid as a stock dividend, on a basis of 20:1 (the “Stock Dividend”), pursuant to which, the Company’s shareholders as at September 24, 2013 received twenty (20) shares of our Company’s common stock for each one (1) share of common stock currently held.
Common stock issued for services, Shares	19,460,448	[1]	650,000	[2]
Private placement - at $0.50 - $1.10, Shares	513,110	[3]
Private placement - at $0.50 - $1.10, Value	512	[3]
Common stock issued for services, Value	19,462	[1]	650	[2]
Conversion of related party payables, Shares	175,624
Conversion of related party payables, Value	175
Common Stock | Officers and Employees
Common stock issued for services, Shares	140,000
Common stock issued for services, Value	197,400
Common Stock | Consulting Services
Common stock issued for services, Shares	13,861,814
Common stock issued for services, Value	26,591,126
Common Stock | Legal Services
Common stock issued for services, Shares	598,634
Common stock issued for services, Value	1,361,561
Common Stock | Management Services
Common stock issued for services, Shares	5,000,000
Common stock issued for services, Value	14,750,000
Common Stock | Private Placement
Private placement - at $0.50 - $1.10, Shares	1,726,910
Private placement - at $0.50 - $1.10, Value	1,075,735
Common Stock | Investor
Common stock issued for services, Shares			20,000
Sale of Stock, Price Per Share			$0.25
Common Stock | Investor 2
Common stock issued for services, Shares			600,000
Sale of Stock, Price Per Share			$0.25
Common Stock | Investor 3
Common stock issued for services, Shares			30,000
Sale of Stock, Price Per Share			$0.25
Additional Paid-In Capital
Private placement - at $0.50 - $1.10, Value	487,798
Common stock issued for services, Value	42,683,225		161,850
Conversion of related party payables, Value	208,281
Warrant
Fair Value Assumptions, Expected Dividend Rate	0.00%
Allocated Share-based Compensation Expense	4,155,467
Warrant | $1,500,000 June 25, 2014 Convertible Note
Warrants, Issued	297,832
Warrant | Himmil Convertible Note
Warrants, Issued	297,832
Exercise Price of Warrants	$2.15
Warrant | Minimum
Fair Value Assumptions, Expected Volatility Rate	120.00%
Fair Value Assumptions, Risk Free Interest Rate	0.20%
Warrant | Maximum
Fair Value Assumptions, Expected Volatility Rate	128.00%
Fair Value Assumptions, Risk Free Interest Rate	0.30%
Warrant | Subscriptions
Warrants, Issued	3,230,000
Fair Value of Warrants	$6,643,981
Warrant | Private Placement
Warrants, Issued	1,599,910
[1]	Common stock issued for services pursuant to: Consulting, Legal, and Management
[2]	Common stock issued for services at $0.25 per share
[3]	3 Private placements - at $0.50, at $1.00, and at $1.10

Note_4_Equity_Summary_of_Warra1

Note 4 Equity: Summary of Warrants Issued (Details) (Warrant, USD $)	12 Months Ended
	Dec. 31, 2014
Warrant
Outstanding, beginning balance	0
Outstanding, Weighted Average Exercise Price, beginning balance	$0
Issued	5,127,742
Issued, Weighted Average Exercise Price	$0.70
Exercised	0
Exercised, Weighted Average Exercise Price	$0
Outstanding, ending balance	5,127,742
Outstanding, Weighted Average Exercise Price, ending balance	$0.70

Note_6_Cash_Details

Note 6 Cash (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Total Cash Balances	$79,624
Foreign Currency Transaction Adjustment	39,767
Canada, Dollars
Total Cash Balances	$46,554

Note_7_Notes_Payable_Details

Note 7 Notes Payable (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 04, 2014	Dec. 31, 2012	Mar. 31, 2014	8-May-14	Jun. 25, 2014	Sep. 01, 2014	Sep. 12, 2014	Oct. 01, 2014	Nov. 25, 2014	Nov. 26, 2014
Proceeds from Convertible Notes	$1,727,000	$0
Accretion expense	1,286,801
Gain (loss) on revaluation of derivative liability	1,559,423	0
Debt Conversion, Original Debt, Amount	145,315	0
Derivative Liability, Fair Value, Gross Liability	389,397	0		0
Loss on excess of fair value of stock issued over convertible note principal	-107,784
Stock issuance liability	145,578
Loss on excess derivative liability over note principal	-436,215	0
Market trading price			$2.04
Notes payable	87,755
LG Capital/Adar Bays Convertible Notes
Debt Instrument, Face Amount					115,000
Debt Instrument, Maturity Date	31-Mar-15
Debt Instrument, Interest Rate, Stated Percentage	8.00%				8.00%
The percentage of the original issue discount for the debt instrument.	5.00%
Proceeds from Convertible Notes	115,000
DebtI nstrument Purchase Price	55,000
Terms of Conversion for Convertible Note	At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock. The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be paid by the Company in common stock.
Derivative Liability	28,211				84,506
Accretion expense	84,506
Gain (loss) on revaluation of derivative liability	56,295
Debt Conversion, Original Debt, Amount	65,321
Derivative Liability, Fair Value, Gross Liability	91,960
Loss on excess of fair value of stock issued over convertible note principal	26,639
Stock issuance liability	65,321
Long-term Debt, Gross	54,875
LG Capital/Adar Bays Convertible Notes | Common Stock
Shares Issued Pursuant to Debt Conversion	1,189,299
Back-end Notes
Debt Instrument, Face Amount	115,000
Debt Instrument, Maturity Date	31-Mar-15
The percentage of the original issue discount for the debt instrument.	5.00%
Proceeds from Convertible Notes	110,000
Terms of Conversion for Convertible Note	the conversion price for each share is 65% of the lowest closing bid price for twenty prior trading days. At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.
Derivative Liability	31,883				80,028
Accretion expense	14,543
Gain (loss) on revaluation of derivative liability	48,145
Long-term Debt, Gross	115,835
JSJ Investments Convertible Note
Debt Instrument, Face Amount						100,000
Debt Instrument, Maturity Date	8-Nov-14
Debt Instrument, Interest Rate, Stated Percentage						12.00%
Terms of Conversion for Convertible Note	The note may be converted to stock at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion.
Derivative Liability	381					129,359
Accretion expense	129,359
Gain (loss) on revaluation of derivative liability	128,978
Debt Conversion, Original Debt, Amount	50,000
Derivative Liability, Fair Value, Gross Liability	96,571
Loss on excess of fair value of stock issued over convertible note principal	46,571
Stock issuance liability	50,000
Long-term Debt, Gross	57,118
Cash Redemption Premium	130.00%
Loss on excess derivative liability over note principal	28,333
JSJ Investments Convertible Note | Common Stock
Shares Issued Pursuant to Debt Conversion	568,064
Typenex Convertible Note
Debt Instrument, Face Amount			1,105,000
Debt Instrument, Maturity Date	4-Nov-15
Debt Instrument, Interest Rate, Stated Percentage			10.00%
Proceeds from Convertible Notes	170,000
DebtI nstrument Purchase Price	1,000,000
Accretion expense	16,453
Debt Conversion, Original Debt, Amount	30,000
Derivative Liability, Fair Value, Gross Liability	64,573
Loss on excess of fair value of stock issued over convertible note principal	34,573
Stock issuance liability	30,000
Long-term Debt, Gross	159,675
Convertible promissory notes discount			100,000
Debt Instrument, Fee Amount			5,000
Conversion price for each lender conversion			$1.65
Beneficial Conversion Feature	41,212
Typenex Convertible Note | Common Stock
Shares Issued Pursuant to Debt Conversion	807,168
Initial Cash Purchase Price
Debt Instrument, Face Amount			170,000
Original issue discount			15,000
Secured investor note #1
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Secured investor note #2
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Secured investor note #3
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Secured investor note #4
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Investor note #5
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Investor note #6
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Investor note #7
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Investor note #8
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Investor note #9
Debt Instrument, Face Amount			85,000
Original issue discount			8,500
Himmil Convertible Note
Debt Instrument, Face Amount	1,500,000						1,500,000
Debt Instrument, Interest Rate, Stated Percentage	18.00%						5.00%
DebtI nstrument Purchase Price	1,000,000
Terms of Conversion for Convertible Note	convertible at the option of the Investor at any time into shares of the Company’s common stock at a conversion price equal to the less of (i) $1.90 and (ii) 70% (60% in the event of default) of the average of the two lowest volume-weighted-average-price of the Common Stock during the 12 consecutive trading days immediately preceding the applicable conversion date.
Derivative Liability	261,209						1,164,745
Accretion expense	603,114
Gain (loss) on revaluation of derivative liability	1,099,709
Debt Conversion, Original Debt, Amount	221,122
Derivative Liability, Fair Value, Gross Liability	503,352
Long-term Debt, Gross	808,043
Loss on excess derivative liability over note principal	360,672
Original issue discount	500,000
Debt Instrument, Redemption, Description	All or part of the then remaining principal amount of the Note may be prepaid at any time at a price equal to 125% of the sum of the remaining principal amount of the Note to be prepaid plus all accrued and unpaid interest thereon.
Debt Instrument, Description	The principal amount of the Note will be reduced by $500,000 if the shares of Common Stock underlying the Note are registered for public resale pursuant to an effective registration statement by August 24, 2014.
Himmil Convertible Note | Common Stock
Shares Issued Pursuant to Debt Conversion	27,822,391
Himmil Convertible Note | Warrant
Derivative Liability	195,927
Accretion expense	101,453
Gain (loss) on revaluation of derivative liability	195,927
Long-term Debt, Gross	1,603,476
Warrants, Issued	297,832
Exercise Price of Warrants	$2.15
KBM Worldwide Convertible Note
Debt Instrument, Face Amount								83,500
Debt Instrument, Maturity Date	1-Jun-15
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Derivative Liability	9,431							85,871
Accretion expense	39,211
Gain (loss) on revaluation of derivative liability	76,440
Long-term Debt, Gross	87,362
Loss on excess derivative liability over note principal	4,967
Debt Conversion, Description	At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock. The conversion price for each share is 58% of the average of the 3 lowest closing bid prices for ten prior trading days.
LG Capital Convertible Note
Debt Instrument, Face Amount									82,688
Debt Instrument, Maturity Date	12-Sep-15
Debt Instrument, Interest Rate, Stated Percentage									8.00%
The percentage of the original issue discount for the debt instrument.	5.00%
DebtI nstrument Purchase Price	78,750
Derivative Liability	8,969								68,933
Accretion expense	21,175
Gain (loss) on revaluation of derivative liability	59,964
Long-term Debt, Gross	86,185
Debt Conversion, Description	The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be payable in common stock.
Green Grow LLC Convertible Note
Debt Instrument, Face Amount										4,450,000
Debt Instrument, Maturity Date	1-Apr-15
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Long-term Debt, Gross	4,560,945
Debt Conversion, Description	The conversion price for each share is 50% of the average of the lowest closing bid price for twenty prior trading days. Interest shall be payable in common stock.
Tangiers Convertible Note
Debt Instrument, Face Amount											220,000
Debt Instrument, Maturity Date	25-Nov-15
Debt Instrument, Interest Rate, Stated Percentage											10.00%
The percentage of the original issue discount for the debt instrument.	5.00%
Proceeds from Convertible Notes	75,000
DebtI nstrument Purchase Price	78,750
Derivative Liability	25,497										78,148
Accretion expense	4,926
Long-term Debt, Gross	84,966
Loss on excess derivative liability over note principal	14,596
Convertible promissory notes discount											7,500
Debt Conversion, Description	The conversion price for each share is 58% of the lowest closing bid prices for ten prior trading days.
$82,688 September 12, 2014 Convertible Note
Gain (loss) on revaluation of derivative liability	52,651
November 26, 2014 KBM Worldwide Convertible Note
Debt Instrument, Face Amount												43,000
Debt Instrument, Maturity Date	28-Aug-15
Debt Instrument, Interest Rate, Stated Percentage												8.00%
Derivative Liability	23,816											61,303
Accretion expense	2,173
Gain (loss) on revaluation of derivative liability	37,487
Long-term Debt, Gross	44,178
Loss on excess derivative liability over note principal	26,621
Debt Conversion, Description	The conversion price for each share is 42% of the lowest three closing bid prices for ten prior trading days.
Demand Promissory Note
Debt Instrument, Maturity Date	30-Sep-15
Debt Instrument, Interest Rate, Stated Percentage										12.00%
Notes payable	171,323
Demand Promissory Note | Canada, Dollars
Notes payable	$200,000

Note_7_Notes_Payable_Schedule_2

Note 7 Notes Payable: Schedule of Fair Value Convertible Debentures (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Convertible Notes Payable, beginning balance	$0	$0
Proceeds from new convertible debt tranches	1,727,000	0
Convertible debt issued on consulting fees	4,450,000
Loss on excess of derivative liability over note principal	436,215	0
Interest accrued on principal	239,434	0
Accretion expense	1,286,801
Conversion Of Convertible Debt	-145,315	0
Convertible Notes Payable, ending balance	5,749,937	0
Derivative Liability of Conversion Price
Accretion expense	1,032,636	0
Warrant
Increase (Decrease) in Derivative Liabilities	-195,927	0
Variable Conversion Price
Increase (Decrease) in Derivative Liabilities	($1,794,105)	$0

Note_7_Notes_Payable_Schedule_3

Note 7 Notes Payable: Schedule of Fair Value of Derivative Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair value of derivative liabilities, beginning balance	$0	$0
Gain on revaluation of derivative liabilities	-1,559,423	0
Fair value of derivative liabilities, ending balance	389,397	0
Inception of New Tranches
Increase in fair value of derivative liability	1,752,893	0
Warrant
Increase in fair value of derivative liability	$195,928	$0

Note_8_Subscription_Agreement_

Note 8 Subscription Agreement (Details) (International Herbs Medical Marijuana Ltd.)	Dec. 31, 2014
International Herbs Medical Marijuana Ltd.
Equity Method Investment, Ownership Percentage	51.00%

Note_9_Property_Details

Note 9 Property (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
	sqft
	acre
Details
Area of Property	67,000
Area of Industrial Building	2.55
Anticipated Final Purchase Price	$2,340,310

Note_10_Income_Taxes_Schedule_3

Note 10 Income Taxes: Schedule of Components of Income Tax (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Current Tax	$0	$0
Deferred tax benefit	-19,217,294	-127,993
Benefits of operating loss carryforwards	19,217,294	127,993
Provision for Income Tax	$0	$0

Note_10_Income_Taxes_Schedule_4

Note 10 Income Taxes: Schedule of Deferred Tax Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Rate		34.00%
Net Operating Loss, Balance	$10,266,101	$1,073,579
Related party interest accrual	9,407	9,407
Related Party Interest Expense		9,407
Warrants issued as compensation	4,155,467
Warrants issued as compensation	1,412,859
Stock compensation expense	199,400
Stock compensation expense	67,796
Stock issued for services	42,702,687	162,500
Stock issued for services	14,518,914
NOL Balance reconciliation, other items	271,377
Other items	92,268
Deferred Tax Assets, Valuation Allowance	19,585,509	368,215
Deferred Tax Assets, Net of Valuation Allowance	0	0
Provision For Income Tax
Deferred Tax Assets, Operating Loss Carryforwards	3,490,474	365,017
Related Party Interest Expense	$3,198	$3,198

Note_10_Income_Taxes_Details

Note 10 Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Increase in Valuation Allowance	$16,998,435
Deferred Tax Assets, Valuation Allowance	$19,585,509	$368,215

Note_10_Income_Taxes_Summary_o1

Note 10 Income Taxes: Summary of Operating Loss Carryforwards Expirations (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating Losses, Amount	$10,266,101	$1,073,579
Tax Year 2020
Operating Loss Carryforwards, Expiration Date	31-Dec-20
Operating Losses, Amount	38,250
Tax Year 2021
Operating Loss Carryforwards, Expiration Date	31-Dec-21
Operating Losses, Amount	12,382
Tax Year 2022
Operating Loss Carryforwards, Expiration Date	31-Dec-22
Operating Losses, Amount	17,151
Tax Year 2023
Operating Loss Carryforwards, Expiration Date	31-Dec-23
Operating Losses, Amount	1,427
Tax Year 2024
Operating Loss Carryforwards, Expiration Date	31-Dec-24
Operating Losses, Amount	529,784
Tax Year 2025
Operating Loss Carryforwards, Expiration Date	31-Dec-25
Operating Losses, Amount	32,564
Tax Year 2026
Operating Loss Carryforwards, Expiration Date	31-Dec-26
Operating Losses, Amount	6,488
Tax Year 2027
Operating Loss Carryforwards, Expiration Date	31-Dec-27
Operating Losses, Amount	7,905
Tax Year 2028
Operating Loss Carryforwards, Expiration Date	31-Dec-28
Operating Losses, Amount	14,696
Tax Year 2029
Operating Loss Carryforwards, Expiration Date	31-Dec-29
Operating Losses, Amount	6,905
Tax Year 2030
Operating Loss Carryforwards, Expiration Date	31-Dec-30
Operating Losses, Amount	8,636
Tax Year 2031
Operating Loss Carryforwards, Expiration Date	31-Dec-31
Operating Losses, Amount	8,035
Tax Year 2032
Operating Loss Carryforwards, Expiration Date	31-Dec-32
Operating Losses, Amount	9,467
Tax Year 2033
Operating Loss Carryforwards, Expiration Date	31-Dec-33
Operating Losses, Amount	367,042
Tax Year 2034
Operating Loss Carryforwards, Expiration Date	31-Dec-34
Operating Losses, Amount	$9,192,522

Note_10_Income_Taxes_Schedule_5

Note 10 Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Expected Tax Provision	$19,217,294	($127,993)
Increase in Valuation Allowance	-19,217,294	127,993
Actual Tax Provision	$0	$0

Note_11_Subsequent_Events_Deta

Note 11 Subsequent Events (Details) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Jan. 20, 2015	Feb. 16, 2015	Jan. 14, 2015	Feb. 19, 2015	Jan. 16, 2015	Jan. 30, 2015	Mar. 12, 2015	Dec. 31, 2013	Sep. 01, 2014
Area of Property	67,000
Common Stock, shares authorized	100,000,000								100,000,000
Common Stock, par or stated value	0.001								$0.00
KBM Worldwide Convertible Note
Debt Instrument, Face Amount										$83,500
Debt Instrument, Maturity Date	1-Jun-15
Debt Instrument, Interest Rate, Stated Percentage										8.00%
Debt Conversion, Description	At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock. The conversion price for each share is 58% of the average of the 3 lowest closing bid prices for ten prior trading days.
Subsequent Event
Area of Property		7,200
Leasing Terms		The rental amount of the current lease is in excess of $200,000 annually, triple net. The lease provides for two five-year tenant renewal options. The lease rate increases at 3 percent per year or CPI, whichever is greater. Total purchase price for the property is $2,250,000, which Medican expects to pay through a combination of mortgage debt and an $850,000 convertible promissory note secured by the property.
Appraisal Value		2,385,000
Common Stock, shares authorized			1,000,000,000
Common Stock, par or stated value			0.001
Subsequent Event | Common Stock
Stockholders' Equity, Reverse Stock Split			reverse split in an amount up to 1:10
Subsequent Event | KBM Worldwide Convertible Note
Debt Instrument, Face Amount				54,000
Debt Instrument, Maturity Date				16-Oct-15
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Conversion, Description				The conversion price for each share is 58% of the lowest three closing bid prices for ten prior trading days.
Subsequent Event | RDW Note
Debt Instrument, Face Amount					25,000	100,000
Debt Instrument, Maturity Date						16-Jul-15
Debt Instrument, Interest Rate, Stated Percentage					10.00%	10.00%
Debt Conversion, Description					The principal and interest underlying the RDW Note is convertible at any time into common stock, at RDW’s option, and will be equal to 35% of the lowest trading price of the Company’s common stock during the twenty consecutive trading days prior to the date on which RDW (or the then-holder of the RDW) elects to convert all or part of the RDW Note.	The conversion price for each share is 35% of the lowest twenty closing bid prices for ten prior trading days.
Debt Instrument, Fee Amount						$45,000
Debt Instrument, Debt Default, Description of Violation or Event of Default					Upon an event of default, the outstanding balance shall immediately be due in cash and shall incur a late fee of $1,000 per day
Debt Instrument, Redemption, Description					In connection therewith, the Company agreed to reserve from its authorized and unissued shares at least the number of shares that may be issuable upon conversion of the note once the Company has increased its authorized shares. The Company may prepay any portion of the principal amount at 130% of such amount along with any accrued interest of the RDW Note at any time upon seven days’ written notice to RDW.
Subsequent Event | Black Mountain Equities
Debt Instrument, Maturity Date							30-Jan-16
Debt Conversion, Description							The conversion price for each share is the lesser of $0.03 or 60% of the lowest three closing bid prices for twenty prior trading days.
Subsequent Event | Vis Vires Note
Debt Conversion, Description								The principal and interest underlying the Vis Vires Note is convertible at any time into common stock, at Vis Vires’s option, and will be equal to 58% of the average of the lowest three trading price of the Company’s common stock during the ten consecutive trading days prior to the date on which Vis Vires (or the then-holder of the Vis Vires) elects to convert all or part of the Vis Vires Note.
Debt Instrument, Debt Default, Description of Violation or Event of Default								Upon an event of default, the outstanding balance shall immediately increase to 150% of the outstanding balance immediately prior to the event of default.
Debt Instrument, Redemption, Description								In connection therewith, the Company agreed to reserve from its authorized and unissued shares at least the number of shares that may be issuable upon conversion of the note once the Company has increased its authorized shares. The Company may prepay any portion of the principal amount at between 115% and 145% of such amount along with any accrued interest of the Vis Vires Note at any time upon seven days’ written notice to Vis Vires.